JP2020503885A5 - - Google Patents

Download PDF

Info

Publication number
JP2020503885A5
JP2020503885A5 JP2019538535A JP2019538535A JP2020503885A5 JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5 JP 2019538535 A JP2019538535 A JP 2019538535A JP 2019538535 A JP2019538535 A JP 2019538535A JP 2020503885 A5 JP2020503885 A5 JP 2020503885A5
Authority
JP
Japan
Prior art keywords
domain
antigen receptor
chimeric antigen
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019538535A
Other languages
English (en)
Japanese (ja)
Other versions
JP7280827B2 (ja
JP2020503885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/014122 external-priority patent/WO2018136570A1/en
Publication of JP2020503885A publication Critical patent/JP2020503885A/ja
Publication of JP2020503885A5 publication Critical patent/JP2020503885A5/ja
Priority to JP2023004031A priority Critical patent/JP7700159B2/ja
Application granted granted Critical
Publication of JP7280827B2 publication Critical patent/JP7280827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019538535A 2017-01-18 2018-01-17 Axlまたはror2に対するキメラ抗原受容体およびその使用方法 Active JP7280827B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023004031A JP7700159B2 (ja) 2017-01-18 2023-01-13 Axlまたはror2に対するキメラ抗原受容体およびその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762447898P 2017-01-18 2017-01-18
US62/447,898 2017-01-18
US201762467059P 2017-03-03 2017-03-03
US62/467,059 2017-03-03
US201762530193P 2017-07-08 2017-07-08
US62/530,193 2017-07-08
PCT/US2018/014122 WO2018136570A1 (en) 2017-01-18 2018-01-17 Chimeric antigen receptors against axl or ror2 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023004031A Division JP7700159B2 (ja) 2017-01-18 2023-01-13 Axlまたはror2に対するキメラ抗原受容体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2020503885A JP2020503885A (ja) 2020-02-06
JP2020503885A5 true JP2020503885A5 (OSRAM) 2021-03-04
JP7280827B2 JP7280827B2 (ja) 2023-05-24

Family

ID=61157332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538535A Active JP7280827B2 (ja) 2017-01-18 2018-01-17 Axlまたはror2に対するキメラ抗原受容体およびその使用方法
JP2023004031A Active JP7700159B2 (ja) 2017-01-18 2023-01-13 Axlまたはror2に対するキメラ抗原受容体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023004031A Active JP7700159B2 (ja) 2017-01-18 2023-01-13 Axlまたはror2に対するキメラ抗原受容体およびその使用方法

Country Status (12)

Country Link
US (2) US12187801B2 (OSRAM)
EP (1) EP3571229A1 (OSRAM)
JP (2) JP7280827B2 (OSRAM)
CN (1) CN110177808A (OSRAM)
AU (1) AU2018211081B2 (OSRAM)
BR (1) BR112019014615A2 (OSRAM)
CA (1) CA3049674A1 (OSRAM)
IL (1) IL267902B1 (OSRAM)
MX (1) MX2019008503A (OSRAM)
SG (2) SG11201906468TA (OSRAM)
TW (1) TWI860971B (OSRAM)
WO (1) WO2018136570A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2764074C2 (ru) 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
WO2020047527A2 (en) * 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
TWI844509B (zh) 2016-05-13 2024-06-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
WO2020050993A2 (en) * 2018-09-07 2020-03-12 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
CN111378039B (zh) * 2018-12-29 2021-08-24 深圳大学 治疗恶性肿瘤的抗体及其应用
CN111378040B (zh) * 2018-12-29 2021-08-10 深圳大学 检测多种恶性肿瘤细胞的抗体及其应用
EP3936523A4 (en) * 2019-01-08 2022-09-07 Shenzhen University ANTIBODY DETECTION OF MALIGNANT TUMOR CELLS AND THEIR APPLICATIONS
EP3715368A1 (en) * 2019-03-28 2020-09-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells
US12479890B2 (en) 2019-04-26 2025-11-25 The University Of North Carolina At Chapel Hill Chimeric antigen receptor constructs and their use in CAR-T cells
CN110317277A (zh) * 2019-07-10 2019-10-11 杭州普科亭生物医药有限公司 嵌合抗原受体及其应用
CN112390894A (zh) * 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
CN112500492B (zh) * 2019-09-13 2023-08-04 中国科学院分子细胞科学卓越创新中心 一种嵌合抗原受体及其用途
KR20220153578A (ko) * 2020-01-23 2022-11-18 엑수마 바이오테크, 코포레이션 Her2에 대한 키메라 항원 수용체 및 이의 사용 방법
US20230111159A1 (en) * 2020-03-05 2023-04-13 Exuma Biotech Corp Methods and compositions for the delivery of modified lymphocyte aggregates
CN114075548B (zh) * 2020-08-13 2023-11-21 广州医科大学附属第二医院 一种靶向axl的car-t细胞及其制备方法和应用
MX2023008662A (es) 2021-01-28 2023-08-01 Allogene Therapeutics Inc Metodos para transducir celulas inmunitarias.
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
CN115125272B (zh) * 2021-03-29 2024-04-19 复旦大学 一种car-t治疗载体及其构建方法和应用
CN116102658B (zh) * 2021-11-09 2025-04-29 四川大学华西医院 基于gas6构建的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
TW197439B (OSRAM) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993023555A1 (en) 1992-05-21 1993-11-25 The Penn State Research Foundation Cultured taxus tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ,インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
DK0796341T3 (da) 1994-12-09 1999-06-14 Imp College Innovations Ltd Identifikation af gener, som tillader tilpasning af en mikroorganisme til en særlig omgivelse
US5821263A (en) 1996-08-26 1998-10-13 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
CA2264227A1 (en) 1996-09-27 1998-04-02 Raymond A. Firestone Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
WO1998058927A1 (en) 1997-06-20 1998-12-30 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2008323206B2 (en) 2007-11-12 2014-08-14 U3 Pharma Gmbh AXL antibodies
MX2010005397A (es) 2007-11-15 2010-10-04 Chugai Pharmaceutical Co Ltd Anticuerpo monoclonal capaz de unirse a anexelekto, y uso del mismo.
ES2661310T3 (es) 2009-03-09 2018-03-28 Bioatla, Llc Proteínas mirac
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
DK2496698T3 (en) 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
JP5940061B2 (ja) 2010-06-18 2016-06-29 ジェネンテック, インコーポレイテッド 抗axl抗体及び使用方法
EP2723377B1 (en) 2011-06-22 2018-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2800975A4 (en) 2012-01-03 2015-12-09 Univ Leland Stanford Junior ANALYSIS AND TARGETING OF ROR2 IN CANCER
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
RU2764074C2 (ru) * 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
US11111288B2 (en) * 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US11673957B2 (en) 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
EP3098237B1 (en) * 2015-05-28 2018-08-01 Universität Zu Köln Anti-toso chimeric antigen receptor and its use
RU2735023C9 (ru) 2015-11-02 2021-06-18 Биоатла, Ллс Условно активные полипептиды
CN109563164A (zh) 2016-04-15 2019-04-02 生物蛋白有限公司 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
KR102873209B1 (ko) 2016-08-31 2025-10-17 바이오아트라, 인코퍼레이티드 조건부 활성 폴리펩티드 및 이를 제조하는 방법
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
JP2020503885A5 (OSRAM)
JP2019528077A5 (OSRAM)
WO2021008610A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP2024023228A5 (OSRAM)
JP2020512820A5 (OSRAM)
JP2016533174A5 (OSRAM)
JP2018172439A5 (OSRAM)
JP2013529190A5 (OSRAM)
JP2020517294A5 (OSRAM)
JP2017504578A5 (OSRAM)
JP2017114866A5 (OSRAM)
JP2020532280A (ja) 細胞により発現される生物学的活性を調節する結合分子
JP2017522891A5 (OSRAM)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2018528786A5 (OSRAM)
JP2014518615A5 (OSRAM)
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2019515666A5 (OSRAM)
CN107286242A (zh) 抗pd‑1的单克隆抗体
JPWO2019232425A5 (OSRAM)
JP2021528382A (ja) 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
TWI690539B (zh) 一個需依賴標靶細胞使T細胞接合及活化之不對稱異二聚Fc-ScFv融合抗體形式及其在癌症治療上之應用
JPWO2021184673A5 (OSRAM)
JP2021514648A (ja) 新規の標的抗原結合部分のための特異性アッセイ
JPWO2019155286A5 (OSRAM)